AIM: To investigate whether the use of statins is associated with colorectal cancer risk. METHODS: We conducted a population-based case-control study in Taiwan. Data were retrospectively collected from the Taiwan National Health Insurance Research Database. Cases consisted of all patients who were aged 50 years and older and had a first-time diagnosis of colorectal cancer between the period 2005 and 2008. The controls were matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multiple logistic regression. RESULTS: We examined 1156 colorectal cancer cases and 4624 controls. The unadjusted ORs for any statin prescription was 1.10 (95% CI = 0.94-1.30) and the adjusted OR was 1.09 (95% CI = 0.91-1.30). When statin use was categorized by cumulative dose, the adjusted ORs were 0.99 (95% CI = 0.78-1.27) for the group with cumulative statin use below 105 defined daily doses (DDDs); 1.07 (95% CI = 0.78-1.49) for the group with cumulative statin use between 106 and 298.66 DDDs; and 1.30 (95% CI = 0.96-1.75) for the group with cumulative statin use of 298.66 DDDs or more compared with nonusers. CONCLUSION: This study does not provide support for a protective effect of statins against colorectal cancer.
AIM: To investigate whether the use of statins is associated with colorectal cancer risk. METHODS: We conducted a population-based case-control study in Taiwan. Data were retrospectively collected from the Taiwan National Health Insurance Research Database. Cases consisted of all patients who were aged 50 years and older and had a first-time diagnosis of colorectal cancer between the period 2005 and 2008. The controls were matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multiple logistic regression. RESULTS: We examined 1156 colorectal cancer cases and 4624 controls. The unadjusted ORs for any statin prescription was 1.10 (95% CI = 0.94-1.30) and the adjusted OR was 1.09 (95% CI = 0.91-1.30). When statin use was categorized by cumulative dose, the adjusted ORs were 0.99 (95% CI = 0.78-1.27) for the group with cumulative statin use below 105 defined daily doses (DDDs); 1.07 (95% CI = 0.78-1.49) for the group with cumulative statin use between 106 and 298.66 DDDs; and 1.30 (95% CI = 0.96-1.75) for the group with cumulative statin use of 298.66 DDDs or more compared with nonusers. CONCLUSION: This study does not provide support for a protective effect of statins against colorectal cancer.
Authors: Eric J Jacobs; Carmen Rodriguez; Kerri A Brady; Cari J Connell; Michael J Thun; Eugenia E Calle Journal: J Natl Cancer Inst Date: 2006-01-04 Impact factor: 13.506
Authors: Patricia F Coogan; Lynn Rosenberg; Julie R Palmer; Brian L Strom; Ann G Zauber; Samuel Shapiro Journal: Epidemiology Date: 2002-05 Impact factor: 4.822
Authors: Jane A Cauley; Joseph M Zmuda; Li-Yung Lui; Teresa A Hillier; Roberta B Ness; Katie L Stone; Steven R Cummings; Douglas C Bauer Journal: J Womens Health (Larchmt) Date: 2003-10 Impact factor: 2.681
Authors: Gemma Ibáñez-Sanz; Elisabet Guinó; Caridad Pontes; Mª Ángeles Quijada-Manuitt; Luisa C de la Peña-Negro; María Aragón; Marga Domínguez; Lorena Rodríguez-Alonso; Alex Blasco; Ana García-Rodríguez; Rosa Morros; Victor Moreno Journal: Sci Rep Date: 2019-09-19 Impact factor: 4.379